ADITXT INC (ADTX) Stock Price, Forecast & Analysis
USA - NASDAQ:ADTX - US0070258027 - Common Stock
ADTX Key Statistics, Chart & Performance
The current stock price of ADTX is 5.76 USD. In the past month the price decreased by -89%. In the past year, price decreased by -99.94%.
ADTX Latest News, Press Relases and Analysis
ADTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.43 | 407.81B | ||
| AMGN | AMGEN INC | 15.53 | 182.80B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.23B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.8 | 110.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.18 | 72.42B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 878.47 | 58.73B | ||
| INSM | INSMED INC | N/A | 40.59B | ||
| NTRA | NATERA INC | N/A | 28.77B | ||
| BIIB | BIOGEN INC | 9.6 | 23.57B | ||
| INCY | INCYTE CORP | 16.85 | 21.12B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.37 | 20.73B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.06 | 14.53B |
Related stock screener links
About ADTX
Company Profile
Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. The company is headquartered in Richmond, Virginia and currently employs 26 full-time employees. The company went IPO on 2020-06-19. The company develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. The company also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
Company Info
ADITXT INC
737 N. Fifth Street, Suite 200
Richmond VIRGINIA 94043 US
CEO: Amro Albanna
Employees: 26
Phone: 19094880844
ADITXT INC / ADTX FAQ
What does ADTX do?
Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. The company is headquartered in Richmond, Virginia and currently employs 26 full-time employees. The company went IPO on 2020-06-19. The company develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. The company also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
What is the stock price of ADITXT INC today?
The current stock price of ADTX is 5.76 USD. The price decreased by -2.54% in the last trading session.
What is the dividend status of ADITXT INC?
ADTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of ADTX stock?
ADTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is ADTX stock listed?
ADTX stock is listed on the Nasdaq exchange.
How is the valuation of ADITXT INC (ADTX) based on its PE ratio?
ADITXT INC (ADTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-28041.66).
What is the ownership structure of ADITXT INC (ADTX)?
You can find the ownership structure of ADITXT INC (ADTX) on the Ownership tab.
ADTX Technical Analysis
ADTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ADTX. ADTX may be in some trouble as it scores bad on both profitability and health.
ADTX Financial Highlights
Over the last trailing twelve months ADTX reported a non-GAAP Earnings per Share(EPS) of -28041.66. The EPS increased by 96.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -94.95% | ||
| ROE | -239.53% | ||
| Debt/Equity | 0.35 |
ADTX Forecast & Estimates
For the next year, analysts expect an EPS growth of -2096.63% and a revenue growth 1584.79% for ADTX